Aug. 7 at 6:08 PM
$TNYA $RCKT $LXEO – Watching these cardiac gene therapy names as a group. The sector’s been completely out of favor, and
$TNYA couldn’t have executed better lately — safety clearance PR + earnings were solid — yet the stock got hammered.
So what gives?
$RCKT held up despite no recent news.
$LXEO and
$TNYA both had updates but dropped.
Looks like market makers are walking
$TNYA down with low liquidity and no buyers in a cold sector.
Possibly some institutions dumping via algo AON strategies. Still, the core issue: nobody’s buying until we see positive trial data.
$TNYA guided for Q4/H2 readouts on 201 and 401 – that’s what matters most.
And yeah,
$1 price threshold looms in October, but don’t forget: they get a 180-day extension via Nasdaq CM if needed. So it’s not game over.
For now, the pressure is likely to continue. But when data hits, this thing could rip. Watch closely.
#biotech #genetherapy #TNYA #smallcaps #longgame
